Cancer risk assessment, primary prevention and chemoprevention in occupational health using chromosomal aberration and sister chromatid exchange (SCE) as biomarkers
Keywords:
benzene, heavy metals, genotoxicity, workplace, exposureAbstract
Genotoxicological investigations serve as tools to detect the damages caused by the environmental and occupational mutagens and carcinogens acquired by the somatic cells. These damages are well demonstrated in the course of genotoxicological monitoring by chromosomal mutation, sister chromatid exchange (SCE), and the blastic transformation activity of peripheral blood lymphocytes (PBL), among workers who were exposed to benzene and heavy metals. Workers exposed to different concentration of benzene were monitored for over 20 years. These studies showed an increase of the chromosomal aberrations in workers exposed to benzene above the 1 ppm. At the same time, parallel to the lowering of benzene levels, a decrease in the cytogenetic parameters to the level of the industrial control was observed, during the active preventional period. The main point of intervention was the improvement of the work-sites including lowering the benzene exposure and convincing the workers to change their life styles avoiding confounding factors (e.g. drugs, alcohol, medication and smoking). This monitoring system was also used to determine the protective effects of some natural products with known antioxidant capacity against the in vivo genotoxic effects of these pollutants. In the case of heavy metal (precious metals, chromium, cadmium and nickel) exposed workers, after a chemoprevention treatment with the nutritional supplement Humetta® containing various antioxidants and chelating agents, the results showed a decrease in genotoxic effects, together with improved health status based on the clinical laboratory data.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.